Class Lawyers Seek $88 Mln in Fees in EpiPen Antitrust Settlement
“Five plaintiffs’ firms are seeking $88 million in legal fees for their lead roles in a $264 million class action antitrust settlement in a case that alleged Viatris Inc, the drugmaker formerly known as Mylan, maneuvered to delay generic competition to the EpiPen allergy treatment. The firms Sharp Law, Keller Rohrback,” reports Reuters in their blog.
“Robbins Geller Rudman & Dowd; Pritzker Levine; and Burns Charest — on Friday asked a U.S. federal court judge in Kansas to grant final approval of the settlement with Mylan, which was sued over its marketing strategy for the life-saving EpiPen auto-injection device. A preliminary deal was announced in February shortly before the start.”
